Since the early 1900s, there has been a thirty-five year increase in peoples’ life expectancy, and roughly half of that is believed to be attributed to pharmaceutical intervention. From a mortality perspective, some progress has been made in doubling the life expectancy at 5-6 years compared to 20 years ago, but the overall impact on a family is akin to that of a cancer, only that this illness doesn’t generate the same level of public attention. Read more. The modus operandi within J&J is, of course, a bit different to what they were used to under the former structure, but let’s not forget that our industry changes all the time. “I am delighted that Jane Griffiths has joined the BAE Systems Board. On the one hand, I have been encouraging them to join the Healthcare Businesswomen’s Association (HBA) and have entered into discussions with them about their individual career development. Yes, we are integrating a business, but, at the end of the day, our focus is, and will continue to be, enhancing and optimizing treatment pathways and delivering improved options for patients.
Compiling digital records is essential to finding out more about the underlying causes of idiopathic PAH.
Our content creates conversations, our voice is the one that matters.The CEO Magazine is more than a business title; it’s a source of information, inspiration and motivation for the world’s most successful leaders, executives, investors and entrepreneurs.
75% of early diagnosis at a young age are female and the disease essentially impacts your ability to have a job and to carry out fundamental tasks you would normally perform in your daily life like doing the housework, climbing the stairs or walking your kids to schools. You have to work hard to preserve it.My formula for dealing with the human dimension has been to try to enact the changes as swiftly as possible because people get unsettled with prolonged uncertainty and that can be disruptive.
She has an impressive record of leading research-led, high technology businesses and brings a wealth of international corporate experience to the Board. Our ability to repatriate business from distributorships and to penetrate “white space countries” where Janssen is present, but Actelion was not, means that we can accelerate treatment for many patient groups.
If you ask people how we are different, I think that’s the first thing they would say. Book a virtual coffee and chat with Laura…for FREE Your Business Kick-Starter Join Here Welcome to “Your Business Kick-Starter” the business community that cares about the success of your business as much as you!
Jane Griffith is the Managing Partner of Leaders International Toronto office. We are using our size and scale to be able to put‘X’ per cent of our expenditure into the companies that will have a positive social impact, as well as provide us with the goods we require. Type II diabetes is one of those, Alzheimer’s is another, and both of those are chronic diseases which cost healthcare systems a lot of time and money. The second, which particularly stood out for me, was that the organisation has a focus on developing its staff. My door is always open to candidly talk about these issues and share ideas.We strive to place the patient at the heart of everything that we do.
Actelion products, meanwhile, benefit from being able to leverage the superior launch capacity and market reach of J&J.There is still a lot of scope for enhancement within the Actelion portfolio: namely new indications that still lie within the pulmonary hypertension (PH) and rare disease space.
It’s a common fallacy that you lose personality with large corporations: with many charismatic leaders, J&J proves this.
Jane Griffiths, global head of Actelion – acquired in 2017 by Johnson & Johnson – discusses her priorities heading up an iconic rare disease-focused biotech and gives her take on a wide range of hot-button industry issues; from the future of M&As to patient-centricity, women in … I’m sure that the owners of many biotechs are now dreaming of emulating what was achieved by the founders of Actelion, but there were a number of variables and factors that enabled us to structure the deal in this way: as there was significant additional value bound up in the original entity which remained post-acquisition, that enabled Idorsia to be a viable entity that could stand on its own feet.
Therefore it is not just about trying to prolong life, but to restore quality of life and prevent, as far as possible, the sorts of lifestyle changes that many patients find themselves having to deal with.A further example of patient centricity is our studying of internet search behavioursWe are doing a lot to raise awareness around this disease area amongst practitioners and the public alike.